{"protocolSection":{"identificationModule":{"nctId":"NCT03663205","orgStudyIdInfo":{"id":"BGB-A317-304"},"secondaryIdInfos":[{"id":"CTR20180032","type":"REGISTRY","domain":"ChinaDrugTrials"}],"organization":{"fullName":"BeiGene","class":"INDUSTRY"},"briefTitle":"A Study Evaluating the Efficacy and Safety of Tislelizumab Versus Chemotherapy in Advanced Non-Squamous Non-small Cell Lung Cancer","officialTitle":"A Phase 3, Open-Label, Multicenter, Randomized Study to Investigate the Efficacy and Safety of Tislelizumab (BGB-A317) (Anti-PD1 Antibody) Combined With Platinum-Pemetrexed Versus Platinum-Pemetrexed Alone as First-line Treatment for Patients With Stage IIIB or IV Non-Squamous Non-Small Cell Lung Cancer"},"statusModule":{"statusVerifiedDate":"2024-09","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2018-07-23","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2020-01-23","type":"ACTUAL"},"completionDateStruct":{"date":"2023-04-26","type":"ACTUAL"},"studyFirstSubmitDate":"2018-08-16","studyFirstSubmitQcDate":"2018-09-07","studyFirstPostDateStruct":{"date":"2018-09-10","type":"ACTUAL"},"resultsFirstSubmitDate":"2024-04-11","resultsFirstSubmitQcDate":"2024-09-26","resultsFirstPostDateStruct":{"date":"2024-11-25","type":"ACTUAL"},"lastUpdateSubmitDate":"2025-02-02","lastUpdatePostDateStruct":{"date":"2025-02-04","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"BeiGene","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":true,"isFdaRegulatedDrug":false,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"This study evaluated the efficacy and safety of tislelizumab in combination with platinum (cisplatin or carboplatin) and pemetrexed compared with platinum and pemetrexed alone as first-line treatment in participants with Stage IIIB or IV non-squamous non-small cell lung cancer (NSCLC)."},"conditionsModule":{"conditions":["Non-Small Cell Lung Cancer"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE3"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":334,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Tislelizumab + Platinum + Pemetrexed","type":"EXPERIMENTAL","description":"Tislelizumab 200 milligrams (mg) administered intravenously (IV) once every 3 weeks plus cisplatin 75 mg/m\\^2 or carboplatin area under the plasma or serum concentration-time curve (AUC) 5 once every 3 weeks for 4 to 6 cycles and pemetrexed 500 mg/m\\^2 once every 3 weeks until unacceptable toxicity or disease progression (each cycle is 21 days)","interventionNames":["Drug: Tislelizumab","Drug: Cisplatin","Drug: Carboplatin","Drug: Pemetrexed"]},{"label":"Platinum + Pemetrexed","type":"ACTIVE_COMPARATOR","description":"Cisplatin 75 mg/m\\^2 or carboplatin AUC 5 once every 3 weeks for 4 to 6 cycles and pemetrexed 500 mg/m\\^2 administered IV once every 3 weeks until unacceptable toxicity or disease progression (each cycle is 21 days)","interventionNames":["Drug: Cisplatin","Drug: Carboplatin","Drug: Pemetrexed"]}],"interventions":[{"type":"DRUG","name":"Tislelizumab","description":"Administered intravenously","armGroupLabels":["Tislelizumab + Platinum + Pemetrexed"],"otherNames":["Tevimbra","BGB-A317"]},{"type":"DRUG","name":"Cisplatin","description":"Administered intravenously","armGroupLabels":["Platinum + Pemetrexed","Tislelizumab + Platinum + Pemetrexed"]},{"type":"DRUG","name":"Carboplatin","description":"Administered intravenously","armGroupLabels":["Platinum + Pemetrexed","Tislelizumab + Platinum + Pemetrexed"]},{"type":"DRUG","name":"Pemetrexed","description":"Administered intravenously","armGroupLabels":["Platinum + Pemetrexed","Tislelizumab + Platinum + Pemetrexed"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Progression Free Survival (PFS) Assessed by Independent Review Committee (IRC) Assessment","description":"PFS is defined as the time from randomization until first documentation of progression or death from any cause, whichever occurs first, as assessed by the IRC per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1","timeFrame":"Through primary analysis data cut-off date of 23JAN2020 (up to approximately 1 year and 6 months)"}],"secondaryOutcomes":[{"measure":"Objective Response Rate (ORR) by IRC Assessment","description":"ORR is defined as the percentage of participants with complete response (CR) or partial response (PR), as assessed by the IRC using RECIST v1.1.","timeFrame":"Through study completion data cut-off date of 26APR2023 (up to approximately 4 years and 9 months)"},{"measure":"Duration of Response (DOR) by IRC Assessment","description":"DOR is defined as the time from the first occurrence of a documented objective response to the time of documented disease progression, or death from any cause, whichever comes first, as assessed by the IRC using RECIST v1.1 in participants with documented objective responses","timeFrame":"Through study completion data cut-off date of 26APR2023 (up to approximately 4 years and 9 months)"},{"measure":"Overall Survival (OS)","description":"OS is defined as the time from randomization until the date of death due to any cause","timeFrame":"Through study completion data cut-off date of 26APR2023 (up to approximately 4 years and 9 months)"},{"measure":"PFS by Investigator Assessment","description":"PFS is defined as the time from randomization until first objectively documented disease progression, or death from any cause, whichever occurs first, as assessed by the investigator per RECIST v1.1","timeFrame":"Through study completion data cut-off date of 26APR2023 (up to approximately 4 years and 9 months)"},{"measure":"ORR by Investigator Assessment","description":"ORR is defined as the percentage of participants with CR or PR, as assessed by the investigator using RECIST v1.1","timeFrame":"Through study completion data cut-off date of 26APR2023 (up to approximately 4 years and 9 months)"},{"measure":"DOR by Investigator Assessment","description":"DOR is defined as the time from the first occurrence of a documented objective response to the time of documented disease progression, or death from any cause, whichever comes first, as assessed by the investigator using RECIST v1.1 in participants with documented objective responses","timeFrame":"Through study completion data cut-off date of 26APR2023 (up to approximately 4 years and 9 months)"},{"measure":"Change From Baseline in European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Lung Cancer (EORTC QLQ-LC13)","description":"Change from baseline in EORTC QLQ-CL13 scores for coughing, dyspnea, and chest pain . The EORTC QLQ-LC13 is a questionnaire that measures lung cancer-specific disease and treatment symptoms. It includes questions about specific symptoms in which participants respond based on a 4-point scale, where 1 is \"not at all\" and 4 is \"very much\". Raw scores are transformed into a 0 to 100 scale via linear transformation. A lower score indicates an improvement in symptoms.","timeFrame":"Baseline to Cycle 5 (each cycle is 21 days)"},{"measure":"Change From Baseline in European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) Global Health Status","description":"Change from baseline in EORTC QLQ-C30 Global Health Status/Quality of Life score. The EORTC QLQ-C30 v3.0 is a questionnaire that assesses quality of life of participants with cancer. It includes global health status and quality of life questions related to overall health in which participants respond based on a 7-point scale, where 1 is very poor and 7 is excellent. Raw scores are transformed into a 0 to 100 scale via linear transformation. A higher score indicates better health outcomes.","timeFrame":"Baseline to Cycle 5 (each cycle is 21 days)"},{"measure":"Number of Participants With Adverse Events","description":"Number of participants with treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs), which includes laboratory tests, physical exams, electrocardiogram results and vital signs, according to National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE) v5.0","timeFrame":"Through study completion data cut-off date of 26APR2023 (up to approximately 4 years and 9 months)"},{"measure":"PFS by IRC Based on Programmed Death Ligand 1 (PD-L1) Expression","description":"PFS is defined as the time from randomization until first documentation of progression or death from any cause, whichever occurs first, as assessed by the IRC per RECIST v1.1, based on PD-L1 expression in tumor cells","timeFrame":"Through study completion data cut-off date of 26APR2023 (up to approximately 4 years and 9 months)"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Age 18-75 years old, male or female, signed informed consent form\n2. Advanced NSCLC diagnosed by pathological or clinical physicians\n3. Eastern Cooperative Oncology Group (ECOG) performance score ≤ 1\n4. Participants must have ≥ 1 measurable lesion as defined per RECIST v1.1\n5. Participants must have no prior systemic chemotherapy for advanced or metastatic NSCLC\n6. Life expectancy ≥ 12 weeks\n7. Participants must have adequate organ function\n8. Male/female is willing to use a highly effective method of birth control\n\nExclusion Criteria:\n\n1. Diagnosed with NSCLC but with epidermal growth factor receptor (EGFR)-sensitizing mutation or anaplastic lymphoma kinase (ALK) gene translocation\n2. Received any approved systemic anticancer therapy within 28 days prior to the initiation of study treatment\n3. Received prior treatment with EGFR inhibitors or ALK inhibitors\n4. Received prior therapies targeting programmed cell death protein-1 (PD-1) or programmed cell death protein ligand-1 (PD-L1)\n5. With history of interstitial lung disease, non-infectious pneumonitis or uncontrolled systemic diseases\n6. Clinically significant pericardial effusion\n7. Severe infections, active leptomeningeal disease or uncontrolled, untreated brain metastasis\n8. Any major surgical procedure ≤ 28 days before randomization\n9. Human immunodeficiency virus (HIV) infection\n10. Participants with untreated hepatitis B or C virus (HBV/HCV)\n11. Active autoimmune diseases or history of autoimmune diseases\n12. History of allergic reactions to chemotherapy\n\nNOTE: Other protocol defined Inclusion/Exclusion criteria may apply.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"75 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Study Director","affiliation":"BeiGene","role":"STUDY_DIRECTOR"}],"locations":[{"facility":"Anhui Provincial Hospital","city":"Hefei","state":"Anhui","zip":"230000","country":"China","geoPoint":{"lat":31.86389,"lon":117.28083}},{"facility":"Cancer Hospital Chinese Academy of Medical Sciences","city":"Beijing","state":"Beijing Municipality","zip":"100021","country":"China","geoPoint":{"lat":39.9075,"lon":116.39723}},{"facility":"Beijing Cancer Hospital","city":"Beijing","state":"Beijing Municipality","zip":"100142","country":"China","geoPoint":{"lat":39.9075,"lon":116.39723}},{"facility":"Beijing Hospital","city":"Beijing","state":"Beijing Municipality","zip":"100730","country":"China","geoPoint":{"lat":39.9075,"lon":116.39723}},{"facility":"Peking Union Medical College Hospital","city":"Beijing","state":"Beijing Municipality","zip":"100730","country":"China","geoPoint":{"lat":39.9075,"lon":116.39723}},{"facility":"Chinese Pla General Hospital","city":"Beijing","state":"Beijing Municipality","zip":"100853","country":"China","geoPoint":{"lat":39.9075,"lon":116.39723}},{"facility":"The Second Affiliated Hospital of Chongqing Medical University","city":"Chongqing","state":"Chongqing Municipality","zip":"400010","country":"China","geoPoint":{"lat":29.56026,"lon":106.55771}},{"facility":"Daping Hospital, Third Military Medical University","city":"Chongqing","state":"Chongqing Municipality","zip":"400042","country":"China","geoPoint":{"lat":29.56026,"lon":106.55771}},{"facility":"Chongqing Three Gorges Central Hospital","city":"Chongqing","state":"Chongqing Municipality","zip":"404000","country":"China","geoPoint":{"lat":29.56026,"lon":106.55771}},{"facility":"Fujian Cancer Hospital","city":"Fuzhou","state":"Fujian","zip":"350014","country":"China","geoPoint":{"lat":26.06139,"lon":119.30611}},{"facility":"The First Affiliated Hospital of Xiamen University","city":"Xiamen","state":"Fujian","zip":"361003","country":"China","geoPoint":{"lat":24.47979,"lon":118.08187}},{"facility":"Cancer Center of Guangzhou Medical University","city":"Guangzhou","state":"Guangdong","zip":"510030","country":"China","geoPoint":{"lat":23.11667,"lon":113.25}},{"facility":"Nanfang Hospital of Southern Medical University","city":"Guangzhou","state":"Guangdong","zip":"510515","country":"China","geoPoint":{"lat":23.11667,"lon":113.25}},{"facility":"Cancer Hospital of Shantou University Medical College","city":"Shantou","state":"Guangdong","zip":"515031","country":"China","geoPoint":{"lat":23.35489,"lon":116.67876}},{"facility":"Affiliated Hospital of Guilin Medical University","city":"Guilin","state":"Guangxi","zip":"541001","country":"China","geoPoint":{"lat":25.28022,"lon":110.29639}},{"facility":"The Peoples Hospital of Guangxi Zhuang Autonomous Region","city":"Nanning","state":"Guangxi","zip":"530021","country":"China","geoPoint":{"lat":22.81667,"lon":108.31667}},{"facility":"Guizhou Cancer Hospital","city":"Guiyang","state":"Guizhou","zip":"550000","country":"China","geoPoint":{"lat":26.58333,"lon":106.71667}},{"facility":"The Affiliated Hospital of Zunyi Medical College","city":"Zunyi","state":"Guizhou","zip":"563000","country":"China","geoPoint":{"lat":27.68667,"lon":106.90722}},{"facility":"Hainan General Hospital","city":"Haikou","state":"Hainan","zip":"570206","country":"China","geoPoint":{"lat":20.03421,"lon":110.34651}},{"facility":"Harbin Medical University Cancer Hospital","city":"Harbin","state":"Heilongjiang","zip":"150000","country":"China","geoPoint":{"lat":45.75,"lon":126.65}},{"facility":"Henan Cancer Hospital","city":"Zhengzhou","state":"Henan","zip":"450000","country":"China","geoPoint":{"lat":34.75778,"lon":113.64861}},{"facility":"The First Affiliated Hospital of Zhengzhou University","city":"Zhengzhou","state":"Henan","zip":"450052","country":"China","geoPoint":{"lat":34.75778,"lon":113.64861}},{"facility":"Hubei Cancer Hospital","city":"Wuhan","state":"Hubei","zip":"430079","country":"China","geoPoint":{"lat":30.58333,"lon":114.26667}},{"facility":"Changsha Central Hospital","city":"Changsha","state":"Hunan","zip":"410004","country":"China","geoPoint":{"lat":28.19874,"lon":112.97087}},{"facility":"Hunan Cancer Hospital","city":"Changsha","state":"Hunan","zip":"410013","country":"China","geoPoint":{"lat":28.19874,"lon":112.97087}},{"facility":"The First Affiliated Hospital of Soochow University Branch Shizi","city":"Suzhou","state":"Jiangsu","zip":"215006","country":"China","geoPoint":{"lat":31.30408,"lon":120.59538}},{"facility":"Xuzhou Central Hospital","city":"Xuzhou","state":"Jiangsu","zip":"221000","country":"China","geoPoint":{"lat":34.20442,"lon":117.28386}},{"facility":"The First Hospital of Jilin University","city":"Changchun","state":"Jilin","zip":"130021","country":"China","geoPoint":{"lat":43.88,"lon":125.32278}},{"facility":"The First Hospital of China Medical University","city":"Shenyang","state":"Liaoning","zip":"110001","country":"China","geoPoint":{"lat":41.79222,"lon":123.43278}},{"facility":"Liaoning Cancer Hospital and Institute","city":"Shenyang","state":"Liaoning","zip":"110042","country":"China","geoPoint":{"lat":41.79222,"lon":123.43278}},{"facility":"The First Affiliated Hospital of Xian Jiaotong University","city":"Xi'an","state":"Shaanxi","zip":"710061","country":"China","geoPoint":{"lat":34.25833,"lon":108.92861}},{"facility":"Qilu Hospital of Shandong University","city":"Jinan","state":"Shandong","zip":"250000","country":"China","geoPoint":{"lat":36.66833,"lon":116.99722}},{"facility":"Jinan Central Hospital","city":"Jinan","state":"Shandong","zip":"250013","country":"China","geoPoint":{"lat":36.66833,"lon":116.99722}},{"facility":"Jinan Military General Hospital","city":"Jinan","state":"Shandong","zip":"250031","country":"China","geoPoint":{"lat":36.66833,"lon":116.99722}},{"facility":"Shandong Cancer Hospital","city":"Jinan","state":"Shandong","zip":"250117","country":"China","geoPoint":{"lat":36.66833,"lon":116.99722}},{"facility":"Weifang Peoples Hospital","city":"Weifang","state":"Shandong","zip":"261000","country":"China","geoPoint":{"lat":36.71,"lon":119.10194}},{"facility":"Fudan University Shanghai Cancer Center","city":"Shanghai","state":"Shanghai Municipality","zip":"200000","country":"China","geoPoint":{"lat":31.22222,"lon":121.45806}},{"facility":"Shanghai Chest Hospital","city":"Shanghai","state":"Shanghai Municipality","zip":"200030","country":"China","geoPoint":{"lat":31.22222,"lon":121.45806}},{"facility":"West China Hospital, Sichuan University","city":"Chengdu","state":"Sichuan","zip":"610041","country":"China","geoPoint":{"lat":30.66667,"lon":104.06667}},{"facility":"Tianjin Medical University General Hospital","city":"Tianjin","state":"Tianjin Municipality","zip":"300052","country":"China","geoPoint":{"lat":39.14222,"lon":117.17667}},{"facility":"Tianjin Medical University Cancer Institute and Hospital","city":"Tianjin","state":"Tianjin Municipality","zip":"300060","country":"China","geoPoint":{"lat":39.14222,"lon":117.17667}},{"facility":"Yunnan Cancer Hospital","city":"Kunming","state":"Yunnan","zip":"650100","country":"China","geoPoint":{"lat":25.03889,"lon":102.71833}},{"facility":"The First Affiliated Hospital, Zhejiang University School of Medicine","city":"Hangzhou","state":"Zhejiang","zip":"310003","country":"China","geoPoint":{"lat":30.29365,"lon":120.16142}},{"facility":"Hangzhou First Peoples Hospital","city":"Hangzhou","state":"Zhejiang","zip":"310006","country":"China","geoPoint":{"lat":30.29365,"lon":120.16142}},{"facility":"Zhejiang University College of Medicine Second Affiliated Hospital","city":"Hangzhou","state":"Zhejiang","zip":"310009","country":"China","geoPoint":{"lat":30.29365,"lon":120.16142}},{"facility":"Sir Run Run Shaw Hospital, Zhejiang University School of Medicine","city":"Hangzhou","state":"Zhejiang","zip":"310016","country":"China","geoPoint":{"lat":30.29365,"lon":120.16142}},{"facility":"Zhejiang Cancer Hospital","city":"Hangzhou","state":"Zhejiang","zip":"310022","country":"China","geoPoint":{"lat":30.29365,"lon":120.16142}}]},"referencesModule":{"references":[{"pmid":"34033975","type":"RESULT","citation":"Lu S, Wang J, Yu Y, Yu X, Hu Y, Ai X, Ma Z, Li X, Zhuang W, Liu Y, Li W, Cui J, Wang D, Liao W, Zhou J, Wang Z, Sun Y, Qiu X, Gao J, Bao Y, Liang L, Wang M. Tislelizumab Plus Chemotherapy as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC (RATIONALE 304): A Randomized Phase 3 Trial. J Thorac Oncol. 2021 Sep;16(9):1512-1522. doi: 10.1016/j.jtho.2021.05.005. Epub 2021 May 23."},{"pmid":"40946254","type":"DERIVED","citation":"Lu S, Wang J, Yu Y, Yu X, Hu Y, Wangjun L, Li X, Liu Y, Li W, Qu X, Bao Y, Wang M. First-Line Tislelizumab Plus Chemotherapy in Advanced Non-Squamous Non-Small Cell Lung Cancer: PD-L1 >/= 50% Subgroup Analysis from the RATIONALE-304 Trial. Oncol Ther. 2025 Dec;13(4):1087-1104. doi: 10.1007/s40487-025-00378-8. Epub 2025 Sep 14."},{"pmid":"35333492","type":"DERIVED","citation":"Lu S, Yu Y, Barnes G, Qiu X, Bao Y, Tang B. Examining the Impact of Tislelizumab Added to Chemotherapy on Health-Related Quality-of-Life Outcomes in Previously Untreated Patients With Nonsquamous Non-Small Cell Lung Cancer. Cancer J. 2022 Mar-Apr 01;28(2):96-104. doi: 10.1097/PPO.0000000000000583."}]},"ipdSharingStatementModule":{"ipdSharing":"YES"}},"resultsSection":{"participantFlowModule":{"recruitmentDetails":"This study was conducted at 47 study centers in China.","groups":[{"id":"FG000","title":"Tislelizumab + Platinum + Pemetrexed","description":"Tislelizumab 200 milligrams (mg) administered intravenously (IV) once every 3 weeks plus cisplatin 75 mg/m\\^2 or carboplatin area under the plasma or serum concentration-time curve (AUC) 5 once every 3 weeks for 4 to 6 cycles and pemetrexed 500 mg/m\\^2 once every 3 weeks until unacceptable toxicity or disease progression (each cycle is 21 days)"},{"id":"FG001","title":"Platinum + Pemetrexed","description":"Cisplatin 75 mg/m\\^2 or carboplatin AUC 5 once every 3 weeks for 4 to 6 cycles and pemetrexed 500 mg/m\\^2 administered IV once every 3 weeks until unacceptable toxicity or disease progression (each cycle is 21 days)"}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"223"},{"groupId":"FG001","numSubjects":"111"}]},{"type":"Randomized But Not Treated","achievements":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"1"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"223"},{"groupId":"FG001","numSubjects":"111"}]}],"dropWithdraws":[{"type":"Death","reasons":[{"groupId":"FG000","numSubjects":"144"},{"groupId":"FG001","numSubjects":"69"}]},{"type":"Sponsor decision","reasons":[{"groupId":"FG000","numSubjects":"53"},{"groupId":"FG001","numSubjects":"19"}]},{"type":"Withdrawal by Subject","reasons":[{"groupId":"FG000","numSubjects":"8"},{"groupId":"FG001","numSubjects":"11"}]},{"type":"Lost to Follow-up","reasons":[{"groupId":"FG000","numSubjects":"7"},{"groupId":"FG001","numSubjects":"9"}]},{"type":"Transferred to long term extension study","reasons":[{"groupId":"FG000","numSubjects":"11"},{"groupId":"FG001","numSubjects":"3"}]}]}]},"baselineCharacteristicsModule":{"populationDescription":"Intent-to-treat (ITT) analysis set included all randomized participants","groups":[{"id":"BG000","title":"Tislelizumab + Platinum + Pemetrexed","description":"Tislelizumab 200 mg administered IV once every 3 weeks plus cisplatin 75 mg/m\\^2 or carboplatin AUC 5 once every 3 weeks for 4 to 6 cycles and pemetrexed 500 mg/m\\^2 once every 3 weeks until unacceptable toxicity or disease progression (each cycle is 21 days)"},{"id":"BG001","title":"Platinum + Pemetrexed","description":"Cisplatin 75 mg/m\\^2 or carboplatin AUC 5 once every 3 weeks for 4 to 6 cycles and pemetrexed 500 mg/m\\^2 administered IV once every 3 weeks until unacceptable toxicity or disease progression (each cycle is 21 days)"},{"id":"BG002","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"223"},{"groupId":"BG001","value":"111"},{"groupId":"BG002","value":"334"}]}],"measures":[{"title":"Age, Continuous","paramType":"MEDIAN","dispersionType":"FULL_RANGE","unitOfMeasure":"Years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"61.0","lowerLimit":"28","upperLimit":"76"},{"groupId":"BG001","value":"62.0","lowerLimit":"25","upperLimit":"75"},{"groupId":"BG002","value":"61.0","lowerLimit":"25","upperLimit":"76"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","calculatePct":false,"classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"55"},{"groupId":"BG001","value":"32"},{"groupId":"BG002","value":"87"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"168"},{"groupId":"BG001","value":"79"},{"groupId":"BG002","value":"247"}]}]}]},{"title":"Race/Ethnicity, Customized","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","calculatePct":false,"classes":[{"title":"Asian","categories":[{"measurements":[{"groupId":"BG000","value":"223"},{"groupId":"BG001","value":"111"},{"groupId":"BG002","value":"334"}]}]},{"title":"Not Hispanic or Latino","categories":[{"measurements":[{"groupId":"BG000","value":"223"},{"groupId":"BG001","value":"111"},{"groupId":"BG002","value":"334"}]}]}]},{"title":"Smoking Status","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","calculatePct":false,"classes":[{"title":"Never","categories":[{"measurements":[{"groupId":"BG000","value":"76"},{"groupId":"BG001","value":"45"},{"groupId":"BG002","value":"121"}]}]},{"title":"Current","categories":[{"measurements":[{"groupId":"BG000","value":"32"},{"groupId":"BG001","value":"13"},{"groupId":"BG002","value":"45"}]}]},{"title":"Former","categories":[{"measurements":[{"groupId":"BG000","value":"115"},{"groupId":"BG001","value":"53"},{"groupId":"BG002","value":"168"}]}]}]},{"title":"PD-L1 Expression in Tumor Cells","populationDescription":"PD-L1 unevaluable refers to the participants without sample collection, not evaluable at baseline, or scored with unqualified sample.","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","calculatePct":false,"classes":[{"title":"<1%","categories":[{"measurements":[{"groupId":"BG000","value":"91"},{"groupId":"BG001","value":"48"},{"groupId":"BG002","value":"139"}]}]},{"title":"1%-49%","categories":[{"measurements":[{"groupId":"BG000","value":"53"},{"groupId":"BG001","value":"27"},{"groupId":"BG002","value":"80"}]}]},{"title":"≥ 50%","categories":[{"measurements":[{"groupId":"BG000","value":"74"},{"groupId":"BG001","value":"36"},{"groupId":"BG002","value":"110"}]}]},{"title":"Unevaluable","categories":[{"measurements":[{"groupId":"BG000","value":"5"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"5"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Progression Free Survival (PFS) Assessed by Independent Review Committee (IRC) Assessment","description":"PFS is defined as the time from randomization until first documentation of progression or death from any cause, whichever occurs first, as assessed by the IRC per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1","populationDescription":"ITT analysis set included all randomized participants","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Months","timeFrame":"Through primary analysis data cut-off date of 23JAN2020 (up to approximately 1 year and 6 months)","groups":[{"id":"OG000","title":"Tislelizumab + Platinum + Pemetrexed","description":"Tislelizumab 200 mg administered IV once every 3 weeks plus cisplatin 75 mg/m\\^2 or carboplatin AUC 5 once every 3 weeks for 4 to 6 cycles and pemetrexed 500 mg/m\\^2 once every 3 weeks until unacceptable toxicity or disease progression (each cycle is 21 days)"},{"id":"OG001","title":"Platinum + Pemetrexed","description":"Cisplatin 75 mg/m\\^2 or carboplatin AUC 5 once every 3 weeks for 4 to 6 cycles and pemetrexed 500 mg/m\\^2 administered IV once every 3 weeks until unacceptable toxicity or disease progression (each cycle is 21 days)"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"223"},{"groupId":"OG001","value":"111"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9.7","lowerLimit":"7.72","upperLimit":"11.53"},{"groupId":"OG001","value":"7.6","lowerLimit":"5.55","upperLimit":"8.02"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.0054","statisticalMethod":"One-sided, Log Rank Test","paramType":"Hazard Ratio (HR)","paramValue":"0.651","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.465","ciUpperLimit":"0.912","estimateComment":"Stratified by stratification factors: disease stage (IIIB or IV) and the level of PD-L1 expression in tumor cells (\\>=50%, 1% to 49%, \\<1%)"}]},{"type":"SECONDARY","title":"Objective Response Rate (ORR) by IRC Assessment","description":"ORR is defined as the percentage of participants with complete response (CR) or partial response (PR), as assessed by the IRC using RECIST v1.1.","populationDescription":"ITT analysis set included all randomized participants","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of participants","timeFrame":"Through study completion data cut-off date of 26APR2023 (up to approximately 4 years and 9 months)","groups":[{"id":"OG000","title":"Tislelizumab + Platinum + Pemetrexed","description":"Tislelizumab 200 mg administered IV once every 3 weeks plus cisplatin 75 mg/m\\^2 or carboplatin AUC 5 once every 3 weeks for 4 to 6 cycles and pemetrexed 500 mg/m\\^2 once every 3 weeks until unacceptable toxicity or disease progression (each cycle is 21 days)"},{"id":"OG001","title":"Platinum + Pemetrexed","description":"Cisplatin 75 mg/m\\^2 or carboplatin AUC 5 once every 3 weeks for 4 to 6 cycles and pemetrexed 500 mg/m\\^2 administered IV once every 3 weeks until unacceptable toxicity or disease progression (each cycle is 21 days)"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"223"},{"groupId":"OG001","value":"111"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"57.8","lowerLimit":"51.1","upperLimit":"64.4"},{"groupId":"OG001","value":"36.9","lowerLimit":"28.0","upperLimit":"46.6"}]}]}]},{"type":"SECONDARY","title":"Duration of Response (DOR) by IRC Assessment","description":"DOR is defined as the time from the first occurrence of a documented objective response to the time of documented disease progression, or death from any cause, whichever comes first, as assessed by the IRC using RECIST v1.1 in participants with documented objective responses","populationDescription":"ITT analysis set included all randomized participants","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Months","timeFrame":"Through study completion data cut-off date of 26APR2023 (up to approximately 4 years and 9 months)","groups":[{"id":"OG000","title":"Tislelizumab + Platinum + Pemetrexed","description":"Tislelizumab 200 mg administered IV once every 3 weeks plus cisplatin 75 mg/m\\^2 or carboplatin AUC 5 once every 3 weeks for 4 to 6 cycles and pemetrexed 500 mg/m\\^2 once every 3 weeks until unacceptable toxicity or disease progression (each cycle is 21 days)"},{"id":"OG001","title":"Platinum + Pemetrexed","description":"Cisplatin 75 mg/m\\^2 or carboplatin AUC 5 once every 3 weeks for 4 to 6 cycles and pemetrexed 500 mg/m\\^2 administered IV once every 3 weeks until unacceptable toxicity or disease progression (each cycle is 21 days)"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"129"},{"groupId":"OG001","value":"41"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10.6","lowerLimit":"8.38","upperLimit":"17.64"},{"groupId":"OG001","value":"7.0","lowerLimit":"4.99","upperLimit":"10.61"}]}]}]},{"type":"SECONDARY","title":"Overall Survival (OS)","description":"OS is defined as the time from randomization until the date of death due to any cause","populationDescription":"ITT analysis set included all randomized participants","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Months","timeFrame":"Through study completion data cut-off date of 26APR2023 (up to approximately 4 years and 9 months)","groups":[{"id":"OG000","title":"Tislelizumab + Platinum + Pemetrexed","description":"Tislelizumab 200 mg administered IV once every 3 weeks plus cisplatin 75 mg/m\\^2 or carboplatin AUC 5 once every 3 weeks for 4 to 6 cycles and pemetrexed 500 mg/m\\^2 once every 3 weeks until unacceptable toxicity or disease progression (each cycle is 21 days)"},{"id":"OG001","title":"Platinum + Pemetrexed","description":"Cisplatin 75 mg/m\\^2 or carboplatin AUC 5 once every 3 weeks for 4 to 6 cycles and pemetrexed 500 mg/m\\^2 administered IV once every 3 weeks until unacceptable toxicity or disease progression (each cycle is 21 days)"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"223"},{"groupId":"OG001","value":"111"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"21.4","lowerLimit":"17.91","upperLimit":"25.40"},{"groupId":"OG001","value":"20.1","lowerLimit":"14.88","upperLimit":"28.12"}]}]}]},{"type":"SECONDARY","title":"PFS by Investigator Assessment","description":"PFS is defined as the time from randomization until first objectively documented disease progression, or death from any cause, whichever occurs first, as assessed by the investigator per RECIST v1.1","populationDescription":"ITT analysis set included all randomized participants","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Months","timeFrame":"Through study completion data cut-off date of 26APR2023 (up to approximately 4 years and 9 months)","groups":[{"id":"OG000","title":"Tislelizumab + Platinum + Pemetrexed","description":"Tislelizumab 200 mg administered IV once every 3 weeks plus cisplatin 75 mg/m\\^2 or carboplatin AUC 5 once every 3 weeks for 4 to 6 cycles and pemetrexed 500 mg/m\\^2 once every 3 weeks until unacceptable toxicity or disease progression (each cycle is 21 days)"},{"id":"OG001","title":"Platinum + Pemetrexed","description":"Cisplatin 75 mg/m\\^2 or carboplatin AUC 5 once every 3 weeks for 4 to 6 cycles and pemetrexed 500 mg/m\\^2 administered IV once every 3 weeks until unacceptable toxicity or disease progression (each cycle is 21 days)"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"223"},{"groupId":"OG001","value":"111"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9.7","lowerLimit":"7.66","upperLimit":"11.70"},{"groupId":"OG001","value":"5.6","lowerLimit":"4.80","upperLimit":"7.66"}]}]}]},{"type":"SECONDARY","title":"ORR by Investigator Assessment","description":"ORR is defined as the percentage of participants with CR or PR, as assessed by the investigator using RECIST v1.1","populationDescription":"ITT analysis set included all randomized participants","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of participants","timeFrame":"Through study completion data cut-off date of 26APR2023 (up to approximately 4 years and 9 months)","groups":[{"id":"OG000","title":"Tislelizumab + Platinum + Pemetrexed","description":"Tislelizumab 200 mg administered IV once every 3 weeks plus cisplatin 75 mg/m\\^2 or carboplatin AUC 5 once every 3 weeks for 4 to 6 cycles and pemetrexed 500 mg/m\\^2 once every 3 weeks until unacceptable toxicity or disease progression (each cycle is 21 days)"},{"id":"OG001","title":"Platinum + Pemetrexed","description":"Cisplatin 75 mg/m\\^2 or carboplatin AUC 5 once every 3 weeks for 4 to 6 cycles and pemetrexed 500 mg/m\\^2 administered IV once every 3 weeks until unacceptable toxicity or disease progression (each cycle is 21 days)"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"223"},{"groupId":"OG001","value":"111"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"57.4","lowerLimit":"50.6","upperLimit":"64.0"},{"groupId":"OG001","value":"36.0","lowerLimit":"27.1","upperLimit":"45.7"}]}]}]},{"type":"SECONDARY","title":"DOR by Investigator Assessment","description":"DOR is defined as the time from the first occurrence of a documented objective response to the time of documented disease progression, or death from any cause, whichever comes first, as assessed by the investigator using RECIST v1.1 in participants with documented objective responses","populationDescription":"ITT analysis set included all randomized participants","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Months","timeFrame":"Through study completion data cut-off date of 26APR2023 (up to approximately 4 years and 9 months)","groups":[{"id":"OG000","title":"Tislelizumab + Platinum + Pemetrexed","description":"Tislelizumab 200 mg administered IV once every 3 weeks plus cisplatin 75 mg/m\\^2 or carboplatin AUC 5 once every 3 weeks for 4 to 6 cycles and pemetrexed 500 mg/m\\^2 once every 3 weeks until unacceptable toxicity or disease progression (each cycle is 21 days)"},{"id":"OG001","title":"Platinum + Pemetrexed","description":"Cisplatin 75 mg/m\\^2 or carboplatin AUC 5 once every 3 weeks for 4 to 6 cycles and pemetrexed 500 mg/m\\^2 administered IV once every 3 weeks until unacceptable toxicity or disease progression (each cycle is 21 days)"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"128"},{"groupId":"OG001","value":"40"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"14.5","lowerLimit":"9.72","upperLimit":"18.66"},{"groupId":"OG001","value":"8.4","lowerLimit":"5.55","upperLimit":"10.38"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Lung Cancer (EORTC QLQ-LC13)","description":"Change from baseline in EORTC QLQ-CL13 scores for coughing, dyspnea, and chest pain . The EORTC QLQ-LC13 is a questionnaire that measures lung cancer-specific disease and treatment symptoms. It includes questions about specific symptoms in which participants respond based on a 4-point scale, where 1 is \"not at all\" and 4 is \"very much\". Raw scores are transformed into a 0 to 100 scale via linear transformation. A lower score indicates an improvement in symptoms.","populationDescription":"Health-related quality of life (HRQoL) analysis set included all randomized participants who received at least 1 dose of study drug and completed at least 1 HRQoL assessment","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Score on a scale","timeFrame":"Baseline to Cycle 5 (each cycle is 21 days)","groups":[{"id":"OG000","title":"Tislelizumab + Platinum + Pemetrexed","description":"Tislelizumab 200 mg administered IV once every 3 weeks plus cisplatin 75 mg/m\\^2 or carboplatin AUC 5 once every 3 weeks for 4 to 6 cycles and pemetrexed 500 mg/m\\^2 once every 3 weeks until unacceptable toxicity or disease progression (each cycle is 21 days)"},{"id":"OG001","title":"Platinum + Pemetrexed","description":"Cisplatin 75 mg/m\\^2 or carboplatin AUC 5 once every 3 weeks for 4 to 6 cycles and pemetrexed 500 mg/m\\^2 administered IV once every 3 weeks until unacceptable toxicity or disease progression (each cycle is 21 days)"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"222"},{"groupId":"OG001","value":"110"}]}],"classes":[{"title":"Coughing","categories":[{"measurements":[{"groupId":"OG000","value":"-13.0","lowerLimit":"-16.6","upperLimit":"-9.4"},{"groupId":"OG001","value":"-10.8","lowerLimit":"-15.7","upperLimit":"-5.9"}]}]},{"title":"Dyspnea","categories":[{"measurements":[{"groupId":"OG000","value":"-1.4","lowerLimit":"-3.5","upperLimit":"0.6"},{"groupId":"OG001","value":"-0.3","lowerLimit":"-3.2","upperLimit":"2.6"}]}]},{"title":"Chest Pain","categories":[{"measurements":[{"groupId":"OG000","value":"-7.4","lowerLimit":"-10.4","upperLimit":"-4.5"},{"groupId":"OG001","value":"-4.2","lowerLimit":"-8.3","upperLimit":"-0.2"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"Least squares mean difference in coughing score","nonInferiorityType":"OTHER","paramType":"Least squares mean difference","paramValue":"-2.2","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-7.4","ciUpperLimit":"3.1","estimateComment":"Based on a constrained longitudinal data analysis model with QLQ-LC13 coughing score on the response variable and treatment by study visit interaction and randomization stratification factors as covariates."},{"groupIds":["OG000","OG001"],"groupDescription":"Least squares mean difference in dyspnea score","nonInferiorityType":"OTHER","paramType":"Least squares mean difference","paramValue":"-1.2","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-4.4","ciUpperLimit":"2.1","estimateComment":"Based on a constrained longitudinal data analysis model with QLQ-LC13 dyspnea score on the response variable and treatment by study visit interaction and randomization stratification factors as covariates."},{"groupIds":["OG000","OG001"],"groupDescription":"Least squares mean difference in chest pain score","nonInferiorityType":"OTHER","paramType":"Least squares mean difference","paramValue":"-3.2","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-7.6","ciUpperLimit":"1.2","estimateComment":"Based on a constrained longitudinal data analysis model with QLQ-LC13 chest pain score on the response variable and treatment by study visit interaction and randomization stratification factors as covariates."}]},{"type":"SECONDARY","title":"Change From Baseline in European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) Global Health Status","description":"Change from baseline in EORTC QLQ-C30 Global Health Status/Quality of Life score. The EORTC QLQ-C30 v3.0 is a questionnaire that assesses quality of life of participants with cancer. It includes global health status and quality of life questions related to overall health in which participants respond based on a 7-point scale, where 1 is very poor and 7 is excellent. Raw scores are transformed into a 0 to 100 scale via linear transformation. A higher score indicates better health outcomes.","populationDescription":"HRQoL analysis set included all randomized participants who received at least 1 dose of study drug and completed at least 1 HRQoL assessment","reportingStatus":"POSTED","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Score on a scale","timeFrame":"Baseline to Cycle 5 (each cycle is 21 days)","groups":[{"id":"OG000","title":"Tislelizumab + Platinum + Pemetrexed","description":"Tislelizumab 200 mg administered IV once every 3 weeks plus cisplatin 75 mg/m\\^2 or carboplatin AUC 5 once every 3 weeks for 4 to 6 cycles and pemetrexed 500 mg/m\\^2 once every 3 weeks until unacceptable toxicity or disease progression (each cycle is 21 days)"},{"id":"OG001","title":"Platinum + Pemetrexed","description":"Cisplatin 75 mg/m\\^2 or carboplatin AUC 5 once every 3 weeks for 4 to 6 cycles and pemetrexed 500 mg/m\\^2 administered IV once every 3 weeks until unacceptable toxicity or disease progression (each cycle is 21 days)"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"222"},{"groupId":"OG001","value":"110"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.9","lowerLimit":"-2.0","upperLimit":"3.8"},{"groupId":"OG001","value":"-3.0","lowerLimit":"-7.3","upperLimit":"1.2"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"Least squares mean difference in Global Health Status/Quality of Life score","nonInferiorityType":"OTHER","paramType":"Least squares mean difference","paramValue":"3.9","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-0.9","ciUpperLimit":"8.7","estimateComment":"Based on a constrained longitudinal data analysis model with QLQ-LC30 Global Health Status/Quality of Life score on the response variable and treatment by study visit interaction and randomization stratification factors as covariates."}]},{"type":"SECONDARY","title":"Number of Participants With Adverse Events","description":"Number of participants with treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs), which includes laboratory tests, physical exams, electrocardiogram results and vital signs, according to National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE) v5.0","populationDescription":"Safety analysis set included all randomized participants who received at least one dose of study treatment","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Through study completion data cut-off date of 26APR2023 (up to approximately 4 years and 9 months)","groups":[{"id":"OG000","title":"Tislelizumab + Platinum + Pemetrexed","description":"Tislelizumab 200 mg administered IV once every 3 weeks plus cisplatin 75 mg/m\\^2 or carboplatin AUC 5 once every 3 weeks for 4 to 6 cycles and pemetrexed 500 mg/m\\^2 once every 3 weeks until unacceptable toxicity or disease progression (each cycle is 21 days)"},{"id":"OG001","title":"Platinum + Pemetrexed","description":"Cisplatin 75 mg/m\\^2 or carboplatin AUC 5 once every 3 weeks for 4 to 6 cycles and pemetrexed 500 mg/m\\^2 administered IV once every 3 weeks until unacceptable toxicity or disease progression (each cycle is 21 days)"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"222"},{"groupId":"OG001","value":"110"}]}],"classes":[{"title":"At least one TEAE","categories":[{"measurements":[{"groupId":"OG000","value":"222"},{"groupId":"OG001","value":"109"}]}]},{"title":"At least one SAE","categories":[{"measurements":[{"groupId":"OG000","value":"99"},{"groupId":"OG001","value":"25"}]}]}]},{"type":"SECONDARY","title":"PFS by IRC Based on Programmed Death Ligand 1 (PD-L1) Expression","description":"PFS is defined as the time from randomization until first documentation of progression or death from any cause, whichever occurs first, as assessed by the IRC per RECIST v1.1, based on PD-L1 expression in tumor cells","populationDescription":"ITT analysis set included all randomized participants; participants evaluable for PD-L expression were included","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Months","timeFrame":"Through study completion data cut-off date of 26APR2023 (up to approximately 4 years and 9 months)","groups":[{"id":"OG000","title":"Tislelizumab + Platinum + Pemetrexed","description":"Tislelizumab 200 mg administered IV once every 3 weeks plus cisplatin 75 mg/m\\^2 or carboplatin AUC 5 once every 3 weeks for 4 to 6 cycles and pemetrexed 500 mg/m\\^2 once every 3 weeks until unacceptable toxicity or disease progression (each cycle is 21 days)"},{"id":"OG001","title":"Platinum + Pemetrexed","description":"Cisplatin 75 mg/m\\^2 or carboplatin AUC 5 once every 3 weeks for 4 to 6 cycles and pemetrexed 500 mg/m\\^2 administered IV once every 3 weeks until unacceptable toxicity or disease progression (each cycle is 21 days)"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"218"},{"groupId":"OG001","value":"111"}]}],"classes":[{"title":"<1% of tumor cells","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"91"},{"groupId":"OG001","value":"48"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"7.6","lowerLimit":"5.0","upperLimit":"9.7"},{"groupId":"OG001","value":"7.6","lowerLimit":"4.3","upperLimit":"7.9"}]}]},{"title":"1% to 49% of tumor cells","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"53"},{"groupId":"OG001","value":"27"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"9.7","lowerLimit":"6.9","upperLimit":"11.7"},{"groupId":"OG001","value":"9.7","lowerLimit":"5.6","upperLimit":"16.8"}]}]},{"title":"≥ 50% of tumor cells","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"74"},{"groupId":"OG001","value":"36"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"17.2","lowerLimit":"11.5","upperLimit":"31.4"},{"groupId":"OG001","value":"4.6","lowerLimit":"3.5","upperLimit":"9.7"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"3","timeFrame":"From first dose up to 30 days after the last dose of study drug; through study completion data cut-off date of 26APR2023 (up to approximately 4 years and 9 months)","description":"All-cause mortality is reported for all randomized participants. Serious and other adverse events includes all randomized participants who received ≥ 1 dose of any study treatment","eventGroups":[{"id":"EG000","title":"Tislelizumab + Platinum + Pemetrexed","description":"Tislelizumab 200 mg administered IV once every 3 weeks plus cisplatin 75 mg/m\\^2 or carboplatin AUC 5 once every 3 weeks for 4 to 6 cycles and pemetrexed 500 mg/m\\^2 once every 3 weeks until unacceptable toxicity or disease progression (each cycle is 21 days)","deathsNumAffected":144,"deathsNumAtRisk":223,"seriousNumAffected":99,"seriousNumAtRisk":222,"otherNumAffected":222,"otherNumAtRisk":222},{"id":"EG001","title":"Platinum + Pemetrexed Alone","description":"Cisplatin 75 mg/m\\^2 or carboplatin AUC 5 once every 3 weeks for 4 to 6 cycles and pemetrexed 500 mg/m\\^2 administered IV once every 3 weeks until unacceptable toxicity or disease progression (each cycle is 21 days)","deathsNumAffected":69,"deathsNumAtRisk":111,"seriousNumAffected":25,"seriousNumAtRisk":110,"otherNumAffected":109,"otherNumAtRisk":110}],"seriousEvents":[{"term":"Agranulocytosis","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":222},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":110}]},{"term":"Anaemia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":222},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":110}]},{"term":"Febrile neutropenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":222},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":110}]},{"term":"Leukopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":222},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":110}]},{"term":"Lymphadenitis","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":222},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":110}]},{"term":"Myelosuppression","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":222},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":110}]},{"term":"Neutropenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":222},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":110}]},{"term":"Pancytopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":222},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":110}]},{"term":"Thrombocytopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":7,"numAffected":7,"numAtRisk":222},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":110}]},{"term":"Atrial fibrillation","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":222},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":110}]},{"term":"Cardiac failure","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":222},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":110}]},{"term":"Cardiac failure acute","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":222},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":110}]},{"term":"Immune-mediated myocarditis","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":222},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":110}]},{"term":"Myocarditis","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":222},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":110}]},{"term":"Right ventricular failure","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":222},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":110}]},{"term":"Thyroid mass","organSystem":"Endocrine disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":222},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":110}]},{"term":"Cataract","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":2,"numAtRisk":222},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":110}]},{"term":"Cataract cortical","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":222},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":110}]},{"term":"Abdominal distension","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":222},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":110}]},{"term":"Abdominal pain","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":222},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":110}]},{"term":"Chronic gastritis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":222},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":110}]},{"term":"Dysphagia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":222},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":110}]},{"term":"Gastritis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":222},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":110}]},{"term":"Gastrointestinal disorder","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":222},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":110}]},{"term":"Haemorrhoids","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":222},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":110}]},{"term":"Immune-mediated enterocolitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":222},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":110}]},{"term":"Immune-mediated gastritis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":222},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":110}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":222},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":110}]},{"term":"Stomatitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":222},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":110}]},{"term":"Upper gastrointestinal haemorrhage","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":222},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":110}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":222},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":110}]},{"term":"Asthenia","organSystem":"General disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":222},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":110}]},{"term":"Chest pain","organSystem":"General disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":222},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":110}]},{"term":"Death","organSystem":"General disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":222},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":110}]},{"term":"Malaise","organSystem":"General disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":222},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":110}]},{"term":"Non-cardiac chest pain","organSystem":"General disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":222},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":110}]},{"term":"Oedema peripheral","organSystem":"General disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":222},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":110}]},{"term":"Pyrexia","organSystem":"General disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":5,"numAtRisk":222},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":110}]},{"term":"Biliary obstruction","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":222},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":110}]},{"term":"Cholecystitis","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":222},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":110}]},{"term":"Cholecystitis acute","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":222},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":110}]},{"term":"Immune-mediated hepatitis","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":222},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":110}]},{"term":"COVID-19","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":222},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":110}]},{"term":"Device related infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":222},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":110}]},{"term":"Klebsiella infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":222},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":110}]},{"term":"Lymph gland infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":222},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":110}]},{"term":"Pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":18,"numAffected":16,"numAtRisk":222},{"groupId":"EG001","numEvents":6,"numAffected":6,"numAtRisk":110}]},{"term":"Rash pustular","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":222},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":110}]},{"term":"Septic shock","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":222},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":110}]},{"term":"Humerus fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":222},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":110}]},{"term":"Lower limb fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":222},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":110}]},{"term":"Spinal compression fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":222},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":110}]},{"term":"Alanine aminotransferase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":222},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":110}]},{"term":"Aspartate aminotransferase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":222},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":110}]},{"term":"Blood creatinine increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":222},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":110}]},{"term":"Gamma-glutamyltransferase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":222},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":110}]},{"term":"Neutrophil count decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":222},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":110}]},{"term":"Platelet count decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":5,"numAtRisk":222},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":110}]},{"term":"White blood cell count decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":222},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":110}]},{"term":"Decreased appetite","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":222},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":110}]},{"term":"Diabetes mellitus","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":222},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":110}]},{"term":"Hyperkalaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":222},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":110}]},{"term":"Hypochloraemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":222},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":110}]},{"term":"Hyponatraemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":222},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":110}]},{"term":"Back pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":222},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":110}]},{"term":"Muscular weakness","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":222},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":110}]},{"term":"Myositis","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":222},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":110}]},{"term":"Osteonecrosis","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":222},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":110}]},{"term":"Cancer pain","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":222},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":110}]},{"term":"Tumour associated fever","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":222},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":110}]},{"term":"Tumour pain","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":222},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":110}]},{"term":"Carpal tunnel syndrome","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":222},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":110}]},{"term":"Cerebellar haemorrhage","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":222},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":110}]},{"term":"Cerebral infarction","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":2,"numAtRisk":222},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":110}]},{"term":"Cerebrovascular disorder","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":222},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":110}]},{"term":"Dizziness","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":222},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":110}]},{"term":"Guillain-Barre syndrome","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":222},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":110}]},{"term":"Ischaemic stroke","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":222},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":110}]},{"term":"Neuralgia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":222},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":110}]},{"term":"Spinal cord compression","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":222},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":110}]},{"term":"Syncope","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":222},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":110}]},{"term":"Completed suicide","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":222},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":110}]},{"term":"Suicide attempt","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":222},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":110}]},{"term":"Acute kidney injury","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":222},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":110}]},{"term":"Glomerulonephritis membranous","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":222},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":110}]},{"term":"Nephrolithiasis","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":222},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":110}]},{"term":"Tubulointerstitial nephritis","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":222},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":110}]},{"term":"Benign prostatic hyperplasia","organSystem":"Reproductive system and breast disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":222},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":110}]},{"term":"Asphyxia","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":222},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":110}]},{"term":"Cough","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":222},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":110}]},{"term":"Dyspnoea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":5,"numAtRisk":222},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":110}]},{"term":"Dyspnoea exertional","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":222},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":110}]},{"term":"Haemoptysis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":222},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":110}]},{"term":"Interstitial lung disease","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":222},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":110}]},{"term":"Pleural effusion","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":4,"numAtRisk":222},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":110}]},{"term":"Pneumonitis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":14,"numAffected":14,"numAtRisk":222},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":110}]},{"term":"Productive cough","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":222},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":110}]},{"term":"Suffocation feeling","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":222},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":110}]},{"term":"Aortic aneurysm","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":222},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":110}]},{"term":"Embolism","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":222},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":110}]},{"term":"Venous thrombosis limb","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":222},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":110}]}],"otherEvents":[{"term":"Anaemia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":578,"numAffected":185,"numAtRisk":222},{"groupId":"EG001","numEvents":182,"numAffected":84,"numAtRisk":110}]},{"term":"Leukopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":209,"numAffected":65,"numAtRisk":222},{"groupId":"EG001","numEvents":93,"numAffected":31,"numAtRisk":110}]},{"term":"Lymphopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":9,"numAffected":7,"numAtRisk":222},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":110}]},{"term":"Neutropenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":383,"numAffected":84,"numAtRisk":222},{"groupId":"EG001","numEvents":133,"numAffected":38,"numAtRisk":110}]},{"term":"Thrombocytopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":138,"numAffected":61,"numAtRisk":222},{"groupId":"EG001","numEvents":67,"numAffected":30,"numAtRisk":110}]},{"term":"Palpitations","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":8,"numAffected":8,"numAtRisk":222},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":110}]},{"term":"Sinus tachycardia","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":22,"numAffected":11,"numAtRisk":222},{"groupId":"EG001","numEvents":3,"numAffected":2,"numAtRisk":110}]},{"term":"Supraventricular extrasystoles","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":15,"numAffected":7,"numAtRisk":222},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":110}]},{"term":"Hyperthyroidism","organSystem":"Endocrine disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":17,"numAffected":12,"numAtRisk":222},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":110}]},{"term":"Hypothyroidism","organSystem":"Endocrine disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":45,"numAffected":28,"numAtRisk":222},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":110}]},{"term":"Abdominal distension","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":10,"numAffected":8,"numAtRisk":222},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":110}]},{"term":"Abdominal pain","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":9,"numAffected":7,"numAtRisk":222},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":110}]},{"term":"Abdominal pain upper","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":9,"numAffected":9,"numAtRisk":222},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":110}]},{"term":"Constipation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":116,"numAffected":57,"numAtRisk":222},{"groupId":"EG001","numEvents":36,"numAffected":26,"numAtRisk":110}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":43,"numAffected":31,"numAtRisk":222},{"groupId":"EG001","numEvents":20,"numAffected":15,"numAtRisk":110}]},{"term":"Mouth ulceration","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":10,"numAffected":8,"numAtRisk":222},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":110}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":332,"numAffected":101,"numAtRisk":222},{"groupId":"EG001","numEvents":86,"numAffected":46,"numAtRisk":110}]},{"term":"Toothache","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":13,"numAffected":11,"numAtRisk":222},{"groupId":"EG001","numEvents":6,"numAffected":5,"numAtRisk":110}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":137,"numAffected":62,"numAtRisk":222},{"groupId":"EG001","numEvents":41,"numAffected":26,"numAtRisk":110}]},{"term":"Asthenia","organSystem":"General disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":68,"numAffected":44,"numAtRisk":222},{"groupId":"EG001","numEvents":22,"numAffected":17,"numAtRisk":110}]},{"term":"Chest discomfort","organSystem":"General disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":222},{"groupId":"EG001","numEvents":6,"numAffected":6,"numAtRisk":110}]},{"term":"Fatigue","organSystem":"General disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":14,"numAffected":11,"numAtRisk":222},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":110}]},{"term":"Influenza like illness","organSystem":"General disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":14,"numAffected":12,"numAtRisk":222},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":110}]},{"term":"Malaise","organSystem":"General disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":97,"numAffected":42,"numAtRisk":222},{"groupId":"EG001","numEvents":40,"numAffected":22,"numAtRisk":110}]},{"term":"Non-cardiac chest pain","organSystem":"General disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":14,"numAffected":14,"numAtRisk":222},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":110}]},{"term":"Oedema peripheral","organSystem":"General disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":21,"numAffected":19,"numAtRisk":222},{"groupId":"EG001","numEvents":9,"numAffected":6,"numAtRisk":110}]},{"term":"Pyrexia","organSystem":"General disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":51,"numAffected":40,"numAtRisk":222},{"groupId":"EG001","numEvents":12,"numAffected":11,"numAtRisk":110}]},{"term":"COVID-19","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":7,"numAffected":7,"numAtRisk":222},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":110}]},{"term":"Pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":20,"numAffected":19,"numAtRisk":222},{"groupId":"EG001","numEvents":8,"numAffected":8,"numAtRisk":110}]},{"term":"Upper respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":23,"numAffected":21,"numAtRisk":222},{"groupId":"EG001","numEvents":7,"numAffected":6,"numAtRisk":110}]},{"term":"Urinary tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":11,"numAffected":10,"numAtRisk":222},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":110}]},{"term":"Alanine aminotransferase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":296,"numAffected":116,"numAtRisk":222},{"groupId":"EG001","numEvents":103,"numAffected":51,"numAtRisk":110}]},{"term":"Alpha hydroxybutyrate dehydrogenase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":19,"numAffected":12,"numAtRisk":222},{"groupId":"EG001","numEvents":8,"numAffected":5,"numAtRisk":110}]},{"term":"Aspartate aminotransferase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":279,"numAffected":104,"numAtRisk":222},{"groupId":"EG001","numEvents":110,"numAffected":52,"numAtRisk":110}]},{"term":"Bilirubin conjugated increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":18,"numAffected":12,"numAtRisk":222},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":110}]},{"term":"Blood albumin decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":3,"numAtRisk":222},{"groupId":"EG001","numEvents":8,"numAffected":6,"numAtRisk":110}]},{"term":"Blood alkaline phosphatase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":58,"numAffected":27,"numAtRisk":222},{"groupId":"EG001","numEvents":17,"numAffected":13,"numAtRisk":110}]},{"term":"Blood bilirubin increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":57,"numAffected":30,"numAtRisk":222},{"groupId":"EG001","numEvents":11,"numAffected":10,"numAtRisk":110}]},{"term":"Blood creatine phosphokinase MB increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":18,"numAffected":12,"numAtRisk":222},{"groupId":"EG001","numEvents":3,"numAffected":2,"numAtRisk":110}]},{"term":"Blood creatine phosphokinase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":29,"numAffected":18,"numAtRisk":222},{"groupId":"EG001","numEvents":7,"numAffected":5,"numAtRisk":110}]},{"term":"Blood creatinine increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":90,"numAffected":46,"numAtRisk":222},{"groupId":"EG001","numEvents":7,"numAffected":5,"numAtRisk":110}]},{"term":"Blood fibrinogen increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":2,"numAtRisk":222},{"groupId":"EG001","numEvents":7,"numAffected":6,"numAtRisk":110}]},{"term":"Blood glucose increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":21,"numAffected":15,"numAtRisk":222},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":110}]},{"term":"Blood lactate dehydrogenase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":88,"numAffected":42,"numAtRisk":222},{"groupId":"EG001","numEvents":26,"numAffected":16,"numAtRisk":110}]},{"term":"Blood sodium decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":222},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":110}]},{"term":"Blood thyroid stimulating hormone increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":16,"numAffected":12,"numAtRisk":222},{"groupId":"EG001","numEvents":7,"numAffected":3,"numAtRisk":110}]},{"term":"Blood urea increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":14,"numAffected":9,"numAtRisk":222},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":110}]},{"term":"Blood uric acid increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":9,"numAffected":5,"numAtRisk":222},{"groupId":"EG001","numEvents":5,"numAffected":4,"numAtRisk":110}]},{"term":"Electrocardiogram QT prolonged","organSystem":"Investigations","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":26,"numAffected":7,"numAtRisk":222},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":110}]},{"term":"Fibrin D dimer increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":8,"numAffected":7,"numAtRisk":222},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":110}]},{"term":"Gamma-glutamyltransferase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":65,"numAffected":34,"numAtRisk":222},{"groupId":"EG001","numEvents":25,"numAffected":18,"numAtRisk":110}]},{"term":"Haemoglobin decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":30,"numAffected":12,"numAtRisk":222},{"groupId":"EG001","numEvents":11,"numAffected":8,"numAtRisk":110}]},{"term":"Lymphocyte count decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":88,"numAffected":29,"numAtRisk":222},{"groupId":"EG001","numEvents":18,"numAffected":6,"numAtRisk":110}]},{"term":"Neutrophil count decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":675,"numAffected":149,"numAtRisk":222},{"groupId":"EG001","numEvents":178,"numAffected":55,"numAtRisk":110}]},{"term":"Platelet count decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":381,"numAffected":121,"numAtRisk":222},{"groupId":"EG001","numEvents":105,"numAffected":46,"numAtRisk":110}]},{"term":"Protein total decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":4,"numAtRisk":222},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":110}]},{"term":"Red blood cell count decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":14,"numAffected":7,"numAtRisk":222},{"groupId":"EG001","numEvents":6,"numAffected":4,"numAtRisk":110}]},{"term":"Weight decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":38,"numAffected":31,"numAtRisk":222},{"groupId":"EG001","numEvents":12,"numAffected":12,"numAtRisk":110}]},{"term":"Weight increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":29,"numAffected":23,"numAtRisk":222},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":110}]},{"term":"White blood cell count decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":715,"numAffected":160,"numAtRisk":222},{"groupId":"EG001","numEvents":195,"numAffected":62,"numAtRisk":110}]},{"term":"Decreased appetite","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":141,"numAffected":81,"numAtRisk":222},{"groupId":"EG001","numEvents":66,"numAffected":36,"numAtRisk":110}]},{"term":"Hypercholesterolaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":8,"numAffected":4,"numAtRisk":222},{"groupId":"EG001","numEvents":7,"numAffected":6,"numAtRisk":110}]},{"term":"Hyperglycaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":82,"numAffected":32,"numAtRisk":222},{"groupId":"EG001","numEvents":20,"numAffected":15,"numAtRisk":110}]},{"term":"Hyperkalaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":10,"numAffected":7,"numAtRisk":222},{"groupId":"EG001","numEvents":13,"numAffected":6,"numAtRisk":110}]},{"term":"Hypertriglyceridaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":12,"numAffected":7,"numAtRisk":222},{"groupId":"EG001","numEvents":8,"numAffected":4,"numAtRisk":110}]},{"term":"Hyperuricaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":36,"numAffected":17,"numAtRisk":222},{"groupId":"EG001","numEvents":19,"numAffected":10,"numAtRisk":110}]},{"term":"Hypoalbuminaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":85,"numAffected":44,"numAtRisk":222},{"groupId":"EG001","numEvents":27,"numAffected":11,"numAtRisk":110}]},{"term":"Hypocalcaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":24,"numAffected":18,"numAtRisk":222},{"groupId":"EG001","numEvents":7,"numAffected":7,"numAtRisk":110}]},{"term":"Hypochloraemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":25,"numAffected":16,"numAtRisk":222},{"groupId":"EG001","numEvents":7,"numAffected":4,"numAtRisk":110}]},{"term":"Hypokalaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":33,"numAffected":27,"numAtRisk":222},{"groupId":"EG001","numEvents":7,"numAffected":5,"numAtRisk":110}]},{"term":"Hypomagnesaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":23,"numAffected":7,"numAtRisk":222},{"groupId":"EG001","numEvents":6,"numAffected":2,"numAtRisk":110}]},{"term":"Hyponatraemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":59,"numAffected":35,"numAtRisk":222},{"groupId":"EG001","numEvents":21,"numAffected":14,"numAtRisk":110}]},{"term":"Hypophosphataemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":18,"numAffected":8,"numAtRisk":222},{"groupId":"EG001","numEvents":7,"numAffected":5,"numAtRisk":110}]},{"term":"Hypoproteinaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":23,"numAffected":19,"numAtRisk":222},{"groupId":"EG001","numEvents":8,"numAffected":4,"numAtRisk":110}]},{"term":"Arthralgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":22,"numAffected":17,"numAtRisk":222},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":110}]},{"term":"Back pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":30,"numAffected":29,"numAtRisk":222},{"groupId":"EG001","numEvents":9,"numAffected":9,"numAtRisk":110}]},{"term":"Musculoskeletal chest pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":4,"numAtRisk":222},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":110}]},{"term":"Pain in extremity","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":23,"numAffected":22,"numAtRisk":222},{"groupId":"EG001","numEvents":9,"numAffected":8,"numAtRisk":110}]},{"term":"Cancer pain","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":8,"numAffected":8,"numAtRisk":222},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":110}]},{"term":"Dizziness","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":39,"numAffected":31,"numAtRisk":222},{"groupId":"EG001","numEvents":9,"numAffected":7,"numAtRisk":110}]},{"term":"Headache","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":17,"numAffected":13,"numAtRisk":222},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":110}]},{"term":"Hypoaesthesia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":9,"numAffected":7,"numAtRisk":222},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":110}]},{"term":"Insomnia","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":35,"numAffected":27,"numAtRisk":222},{"groupId":"EG001","numEvents":17,"numAffected":16,"numAtRisk":110}]},{"term":"Proteinuria","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":12,"numAffected":8,"numAtRisk":222},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":110}]},{"term":"Cough","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":42,"numAffected":37,"numAtRisk":222},{"groupId":"EG001","numEvents":12,"numAffected":10,"numAtRisk":110}]},{"term":"Dyspnoea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":30,"numAffected":27,"numAtRisk":222},{"groupId":"EG001","numEvents":8,"numAffected":7,"numAtRisk":110}]},{"term":"Haemoptysis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":23,"numAffected":17,"numAtRisk":222},{"groupId":"EG001","numEvents":11,"numAffected":9,"numAtRisk":110}]},{"term":"Hiccups","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":9,"numAffected":6,"numAtRisk":222},{"groupId":"EG001","numEvents":7,"numAffected":4,"numAtRisk":110}]},{"term":"Oropharyngeal pain","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":8,"numAffected":8,"numAtRisk":222},{"groupId":"EG001","numEvents":3,"numAffected":2,"numAtRisk":110}]},{"term":"Pneumonitis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":14,"numAffected":14,"numAtRisk":222},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":110}]},{"term":"Productive cough","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":27,"numAffected":25,"numAtRisk":222},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":110}]},{"term":"Alopecia","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":26,"numAffected":22,"numAtRisk":222},{"groupId":"EG001","numEvents":8,"numAffected":7,"numAtRisk":110}]},{"term":"Pruritus","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":17,"numAffected":14,"numAtRisk":222},{"groupId":"EG001","numEvents":4,"numAffected":2,"numAtRisk":110}]},{"term":"Rash","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":56,"numAffected":39,"numAtRisk":222},{"groupId":"EG001","numEvents":15,"numAffected":13,"numAtRisk":110}]},{"term":"Hypertension","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 25.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":8,"numAffected":7,"numAtRisk":222},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":110}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"OTHER","restrictiveAgreement":true,"otherDetails":"BeiGene has 18 months from the end of the study at all sites to publish overall study results. After the 1st multi-site publication or the expiration of publication period, Investigators are free to publish/present the results of the study. Investigators must submit all draft publications/presentations to us for review 60 days prior to the planned publication/presentation date. BeiGene may request deletion of its confidential information \\& may request a further delay to protect its IP rights."},"pointOfContact":{"title":"Study Director","organization":"BeiGene","email":"clinicaltrials@beigene.com","phone":"1-877-828-5568"}}},"documentSection":{"largeDocumentModule":{"largeDocs":[{"typeAbbrev":"Prot","hasProtocol":true,"hasSap":false,"hasIcf":false,"label":"Study Protocol","date":"2019-01-24","uploadDate":"2024-04-11T19:29","filename":"Prot_000.pdf","size":1324199},{"typeAbbrev":"SAP","hasProtocol":false,"hasSap":true,"hasIcf":false,"label":"Statistical Analysis Plan","date":"2020-02-18","uploadDate":"2024-04-11T19:30","filename":"SAP_001.pdf","size":842380}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2025-12-17"},"conditionBrowseModule":{"meshes":[{"id":"D002289","term":"Carcinoma, Non-Small-Cell Lung"}],"ancestors":[{"id":"D002283","term":"Carcinoma, Bronchogenic"},{"id":"D001984","term":"Bronchial Neoplasms"},{"id":"D008175","term":"Lung Neoplasms"},{"id":"D012142","term":"Respiratory Tract Neoplasms"},{"id":"D013899","term":"Thoracic Neoplasms"},{"id":"D009371","term":"Neoplasms by Site"},{"id":"D009369","term":"Neoplasms"},{"id":"D008171","term":"Lung Diseases"},{"id":"D012140","term":"Respiratory Tract Diseases"}]},"interventionBrowseModule":{"meshes":[{"id":"C000707970","term":"tislelizumab"},{"id":"D002945","term":"Cisplatin"},{"id":"D016190","term":"Carboplatin"},{"id":"D000068437","term":"Pemetrexed"}],"ancestors":[{"id":"D017606","term":"Chlorine Compounds"},{"id":"D007287","term":"Inorganic Chemicals"},{"id":"D017672","term":"Nitrogen Compounds"},{"id":"D017671","term":"Platinum Compounds"},{"id":"D056831","term":"Coordination Complexes"},{"id":"D009930","term":"Organic Chemicals"},{"id":"D006147","term":"Guanine"},{"id":"D007042","term":"Hypoxanthines"},{"id":"D011688","term":"Purinones"},{"id":"D011687","term":"Purines"},{"id":"D006574","term":"Heterocyclic Compounds, 2-Ring"},{"id":"D000072471","term":"Heterocyclic Compounds, Fused-Ring"},{"id":"D006571","term":"Heterocyclic Compounds"},{"id":"D005971","term":"Glutamates"},{"id":"D024342","term":"Amino Acids, Acidic"},{"id":"D000596","term":"Amino Acids"},{"id":"D000602","term":"Amino Acids, Peptides, and Proteins"},{"id":"D000600","term":"Amino Acids, Dicarboxylic"}]}},"hasResults":true}